Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 151 | 4.340 |
Why?
|
| Rhinitis | 12 | 2023 | 135 | 3.760 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 60 | 1.620 |
Why?
|
| Nasal Polyps | 6 | 2023 | 50 | 1.330 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 104 | 1.160 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 57 | 1.130 |
Why?
|
| Endoscopy | 9 | 2023 | 168 | 0.980 |
Why?
|
| Chronic Disease | 11 | 2023 | 384 | 0.870 |
Why?
|
| Betacoronavirus | 5 | 2020 | 62 | 0.780 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 71 | 0.750 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 75 | 0.750 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 16 | 0.730 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 16 | 0.650 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 178 | 0.600 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 12 | 0.590 |
Why?
|
| Neutrophils | 1 | 2018 | 83 | 0.570 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3156 | 0.560 |
Why?
|
| Humans | 34 | 2023 | 24703 | 0.560 |
Why?
|
| Otolaryngology | 4 | 2021 | 24 | 0.550 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.540 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.530 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.530 |
Why?
|
| Aspergillosis | 1 | 2017 | 13 | 0.530 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 35 | 0.520 |
Why?
|
| Middle Aged | 15 | 2023 | 8294 | 0.400 |
Why?
|
| Adult | 11 | 2023 | 7255 | 0.360 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 26 | 0.360 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 25 | 0.330 |
Why?
|
| Simulation Training | 2 | 2020 | 35 | 0.320 |
Why?
|
| Nose | 2 | 2021 | 32 | 0.310 |
Why?
|
| Male | 14 | 2021 | 13669 | 0.300 |
Why?
|
| Female | 14 | 2021 | 14048 | 0.300 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 17 | 0.280 |
Why?
|
| Internship and Residency | 2 | 2021 | 199 | 0.280 |
Why?
|
| Aged | 10 | 2023 | 8382 | 0.260 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 63 | 0.240 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 7 | 0.230 |
Why?
|
| Skull Base | 2 | 2023 | 30 | 0.230 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 814 | 0.230 |
Why?
|
| Inflammation | 3 | 2023 | 258 | 0.220 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 12 | 0.210 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 13 | 0.210 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 47 | 0.200 |
Why?
|
| Pandemics | 5 | 2020 | 190 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 113 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3208 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 45 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 62 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2021 | 48 | 0.180 |
Why?
|
| Child | 2 | 2022 | 1131 | 0.180 |
Why?
|
| Professional Role | 1 | 2021 | 28 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 46 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 11 | 0.180 |
Why?
|
| Air Pollution | 1 | 2021 | 14 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 55 | 0.170 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 278 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 4 | 0.170 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 20 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 15 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 613 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.170 |
Why?
|
| Smell | 1 | 2020 | 16 | 0.170 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.170 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 17 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 71 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 136 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Surgeons | 1 | 2021 | 82 | 0.160 |
Why?
|
| Sella Turcica | 1 | 2019 | 4 | 0.160 |
Why?
|
| Surgical Wound | 1 | 2019 | 10 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 118 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 29 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 88 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 65 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 50 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 315 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 74 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 280 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 113 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 30 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 151 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 198 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 1847 | 0.140 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.140 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.140 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.130 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 39 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 183 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 160 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4509 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 437 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 864 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 211 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 674 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1612 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 49 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 231 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 332 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 315 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 285 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 858 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2099 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 1992 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 20 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 28 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 555 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 3 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 12 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 21 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 10 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 34 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 29 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 138 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 16 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 17 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 95 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 39 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 303 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 365 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 33 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 25 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 19 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 33 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 73 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 29 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 57 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 53 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 24 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 157 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 41 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 177 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 279 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 411 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 598 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 165 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 172 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 304 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 728 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1327 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 372 | 0.030 |
Why?
|
| United States | 1 | 2020 | 1873 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(57)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_